Nasus Pharma's Loss Balloons as Cash Clock Ticks — Can a Nasal Spray Bet Justify the Burn?

Shares of Nasus Pharma (NSRX) slid 9% to $3.37 after the Tel Aviv-based clinical-stage biotech reported first-half results that spooked investors with a dramatically wider loss and a cash runway that stretches only about ten more months. The question now: can the company's promising nasal-spray drug candidates reach the finish line before the money runs out?

• The Loss More Than Quadrupled, and the Spending Explains Why. Nasus reported a first-half 2026 net loss of $5.9 million, compared with $1.3 million a year ago.

Loss per share ballooned to $0.54 from $0.17. The main culprit: research and development expenses surged to $2.6 million from just $0.3 million, driven by costs tied to developing its lead intranasal epinephrine powder for severe allergic reactions. That's the kind of spending ramp that's normal for a biotech entering late-stage trials — but it stings when you have no revenue to offset it.

• The Cash Cushion Is Thin, and the Going-Concern Warning Hasn't Gone Away. Cash and short-term deposits stood at $11.9 million as of June 30, up from $4.3 million at year-end 2025 , thanks largely to a $15 million private placement of shares and warrants. But at the current burn rate, Nasus expects that money will last only through the second quarter of 2027.

The company has warned it "cannot be certain that additional funding will be available" and that a shortfall could force it to delay or eliminate programs, risking its ability to continue as a going concern. Translation: another dilutive capital raise is virtually guaranteed.

• The Clinical Milestones Are Real — and They're Close. Phase 2 results for the lead drug showed it delivered therapeutic epinephrine levels faster and more reliably than the EpiPen.

A pivotal late-stage trial is on track to start in Q4 2026, with top-line data expected in Q1 2027.

Management calls this "a growing $2 billion market opportunity currently dominated by injectables." That's a legitimate commercial prize — if the company can fund its way to a regulatory filing.

• New CEO Inherits a Sprint Against the Clock. Pharma veteran Brendan O'Grady took over as CEO on July 27, bringing three decades of commercialization and deal-making experience. His most urgent job isn't selling a drug — it's raising the next round of capital without crushing existing shareholders through heavy dilution. Investors should watch for partnership deals or further equity raises in the coming months as the true signal of whether this story holds together.